Matt Foehr : Yeah, yeah, thanks, Puneet. Yeah, we didn’t cover it in prepared remarks today. We were highlighting the launch of the heavy chain only chicken that we will do in Q4. But you’re right to bring up part of the rationale for the OmniTaur platform and for acquiring the business where that originally resided, was that it opens the possibility for us to engineer those unique cow-like properties of long CDR-H3 into a humanized chicken host. And there’s a lot of science behind that. And our team is doing great work progressing that, something that we are very excited about, and we feel we’re uniquely positioned, perhaps the only people on the planet that can do that. And that is a program we will be talking more about in the future.
And it’s the kind of innovation that I think attracts partners to us, because they realize the impact that, that can have, especially in areas like CNS diseases, or other infectious diseases or emergency settings or variety of targets that having that structural characteristic built into a humanized chicken host creates some pretty substantial and meaningful opportunities downstream, especially well matched with our capabilities around ion channels and transporters, as well, because ion channels and transporters are targets where that technology could be even more meaningful. So you pair that with our extreme high throughput electrophysiology capabilities that were built up over many, many years, we’re talking decades that we believe we may have some of the largest capacity in the world, anywhere in the world for screening ion channel and transporters.
So you pair something like that capability, they are engineering in, in OmniTaur, OmniTaur like chicken, if you will, to just use general terms, that’s something that could have a pretty significant impact to the industry downstream. And that’s something we expect we’ll be talking more about in the future. But it’s just another example of some of the things we’re working on around tech expansion and advancement internally.
Puneet Souda: Got it. Super, and congrats on the first quarter call and it’s a solid one. Thank you.
Kurt Gustafson : Thank you.
Matt Foehr : Thanks Puneet.
Operator: Thank you. And your next question comes f rom the line of Yuan Zhi from B. Riley. Please go ahead.
Yuan Zhi: Thank you for taking our questions. And I have two of them. Matt some of your peers are using AI to generate antibodies. Just want to hear when you talk with your potential customers, has this topic being discussed with them? And what factors of your platform do you think will account with customers, your platform is the right choice.
Matt Foehr : Yeah, thanks. So a couple of comments I’ll make. Really we — at the core of our technology is what we call biological intelligence, right. And that’s based in a foundation really that antibodies generated in vivo are superior from other sources largely because they’re naturally optimized through an iterative process that preferentially selects antibodies with excellent specificity and developability profiles, right. And that ability of the immune system of our engineered transgenic animals is something we’ve been uniquely positioned to do, but also is developed over millions and millions of years of evolution, right. So those optimized antibodies, and the ability of our animals to do that is what we call biological intelligence.
This approach really increases efficiency and probability of success. It’s what drives a lot of partners to us. And we believe it also helps limit the attrition of antibody candidates in the clinic. That said, we obviously leverage in silico tools here all the time, right, spread across our three scientific sites here in Emeryville, in Tucson, Arizona, where we have a dedicated in silico team with a long history of modeling and structural modeling, and a whole host of other capabilities, as well as our team in Durham, North Carolina. So I think it may be a little under appreciated that here for many years, we’ve built up a suite of in silico tools for therapeutic antibody discovery and optimization that are really woven through and paired with our technologies.